Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
株式のランク #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
株価
$17.64
時価総額
$32.65B
変化(1日)
-3.24%
変化(1年)
-23.70%
JP
取引 Daiichi Sankyo Company, Limited (DSNKY)

カテゴリー

Daiichi Sankyo Company, Limited(DSNKY)の配当履歴
Daiichi Sankyo Company, Limited(証券コード:DSNKY)は合計で36回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:$7.57
配当利回り(TTM):0.0245
2009から2026までのDaiichi Sankyo Company, Limited(DSNKY)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 1.13%
2020 $0.2388 11.07%
2019 $0.215 2.87%
2018 $0.209 0.14%
2017 $0.2087 5.51%
2016 $0.1978 -43.47%
2015 $0.3499 -36.15%
2014 $0.548 -14.11%
2013 $0.638 -45.88%
2012 $1.18 52.19%
2011 $0.7746 7.33%
2010 $0.7217 -5.08%
2009 $0.7603 0.00%
すべての配当支払いの一覧
配当 変化
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 -66.29%
2020 $0.7165 11.10%
2019 $0.6449 2.85%
2018 $0.627 0.14%
2017 $0.6261 5.51%
2016 $0.5934 4.77%
2015 $0.5664 3.34%
2014 $0.5481 -8.44%
2013 $0.5986 -83.08%
2012 $3.54 368.46%
2011 $0.755 9.23%
2010 $0.6912 -9.09%
2009 $0.7603 0.00%
同業他社や競合企業の配当履歴
企業 配当支払い回数
215.00%
US
67.00%
GB
225.00%
US
53.00%
US
32.00%
CH